Novartis agrees to pay $678M
NEW YORK (AP) — Novartis Pharmaceutical Corp. will pay $678 million to the U.S. government and various states to settle a lawsuit over a sham speaker program that distributed cash, expensive dinners and other treats to induce doctors to prescribe its products, federal authorities announced Wednesday.
The settlement of the lawsuit was announced by Acting Manhattan U.S. Attorney Audrey Strauss, who said the company splurged on “speaking fees, exorbitant meals, and top-shelf alcohol that were nothing more than bribes to get doctors across the country to prescribe Novartis’ drugs.”
Messages seeking comment were left with lawyers for Novartis Pharmaceuticals, which is part of Swiss drug manufacturer Novartis International AG.
Vas Narasimhan, chief executive of Novartis, said in a statement that the company has already changed, “with new leadership, a stronger culture, and a more comprehensive commitment to ethics embedded at the heart of our company.”
“With these agreements we mark an important milestone on our journey to build trust with society as we continue re-imagining medicine to improve and extend lives all around the world,” Narasimhan said.
The settlement resolves a 2011 whistleblower lawsuit accusing Novartis of violating the federal False Claims Act and Anti-Kickback Statute.
The company admitted giving doctors cash, golf and fishing trips, and lavish meals at some of the nation’s fanciest restaurants to induce them to prescribe Novartis cardiovascular and diabetes drugs that were reimbursed by federal healthcare programs, the government said in a release.
Federal authorities alleged that Novartis earned hundreds of millions of dollars in federal reimbursements for selling drugs sold by doctors benefiting from tens of thousands of sham educational events at high-end restaurants and other venues.